Kurbegovic A, Trudel M. Acute kidney injury induces hallmarks of polycystic kidney disease.
ACUTE KIDNEY INJURY (AKI) is described as a sudden loss of renal function that is of high incidence (ϳ5-10%) in critically ill patients with multiple organ failure and sepsis. One of the most common causes of AKI is renal ischemia that occurs in different clinical settings like kidney transplantation. Patients that recover from AKI are at significant increased risk to develop chronic kidney disease (CKD) (6) .
Human autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic diseases manifested by bilateral renal cysts. ADPKD patients progress to end-stage renal failure frequently at mid-age and then require renal support or replacement therapy. ADPKD is primarily caused by mutations in the PKD1 and PKD2 genes, encoding the protein polycystin-1 (PC1) and polycystin-2 (PC2), respectively. The exact cystogenic mechanism is not clearly defined in humans. Loss of heterozygosity of PKD1 was reported in a minority of renal cysts, whereas a sustained and even increased PKD1 transcript and/or PC1 protein levels are detected in kidney homogenates and in the majority of cysts (26, 50) . A more severe ADPKD phenotype was described in the contiguous human gene syndrome due to mutations in PKD1 and in the adjacent TSC2 gene. Tuberin, the product of the TSC2 gene, was found to physically interact with PC1 (42) .
In the mouse, dosage-reduced Pkd1 alleles lead to variable progression of renal cystic disease whereas Pkd1 inactivation in mature kidneys results in mild or focal cysts (18, 38) . More recently, mouse models with a PKD1 clinical-like allele expressing only the equivalent GPS/GAIN extracellular cleaved form of Pc1, Pkd1 extra (Pkd1 3043X ), was generated. These Pkd1 extra mice develop gradual progressive renal cystogenesis detectable by ϳ15 mo, recapitulating ADPKD characteristics, possibly involving a Pc2 dosage-increased mechanism (24) . Pkd1 full-length dosage increased in Pkd1 TAG transgenic mice lead to a cystic phenotype associated with longer primary cilia in tubular epithelial cells (23) , as also observed in renaltargeted Pkd1 (SBPkd1 TAG ) mice (46) . Disease severity and onset of renal insufficiency in the Pkd1 TAG mice correlated with increased levels of Pkd1, consistent with human ADPKD studies and a dosage-dependent pathogenetic mechanism (23) .
A considerable number of AKI studies in animals have focused on the short-term molecular and cellular events from a couple of hours to a few days after ischemia-reperfusion injury (IRI) to study the damage and repair mechanisms. Renal regeneration from AKI in normal mice is reported to occur within a few days, probably via activation of a program linked to cellular proliferation, as in renal development (37) . However, failing to switch off the repair mechanism may result in continuous activation of numerous genes and renal pathological damage (54) , consistent with frequent development of CKD in patients post-AKI. The few mid-and long-term AKI studies (Ͼ6 wk) in mice and rats reported kidney anomalies, including tubular atrophy, dilatations/cysts, interstitial fibrosis, and inflammation (4, 13, 34) .
Presently, kidney injury is considered as a "modifier" in dosage-reduced Pkd1 murine models. Particularly, the variable progression or penetrance of cystogenesis in adult Pkd1 dosage-reduced kidneys can be overcome by additional stimuli such as toxic damage or AKI. Upon induction of bilateral injury, adult Pkd1-deficient kidneys acquire cysts more rapidly, one within 2 wk (44) whereas the others exhibit dilatations at 5-6 wk (1) and cysts by 10 wk (18) . However, the exact mechanisms underlying this effect and the interconnection between AKI and Pkd1 dose-dependent cystogenesis remain to be elucidated.
The primary objective of this study was to investigate whether AKI is a modifier of cystogenesis from clinical-like and dosage-increased Pkd1 alleles as a step toward dissection of the global cellular and molecular interaction(s). In fact, transient IRI in a low Pkd1 dosage-increased mouse line, Pkd1 TAG , in two Pkd1 extra lines with slow PKD progression (23, 24) , and in nontransgenic (non-Tg) controls reproducibly cause typical PKD cystogenesis independently of the genotype. This IRI cystogenic mechanism was associated not only with markedly elevated Pc1 and Pc2 levels but also with a persistent increase in hypoxia-inducible factor 1␣ (Hif1␣) levels and stimulation of both the Wnt and mammalian target of rapamycin (mTOR) signaling pathways. Our studies provide evidence that AKI is sufficient to induce cystogenesis and reveal a novel cross talk with ADPKD signaling pathways.
METHODS
Unilateral IRI. Experiments were carried out in IRI-induced transgenic Pkd1 extra2/39 (n ϭ 27), Pkd1TAG6 (n ϭ 9), and their control non-Tg littermates (n ϭ 63) as well as in C57BL/6J sham-operated (n ϭ 20) male mice. High dosage-increase Pkd1TAG26 transgenic mice were used as controls. All transgenic mice were backcrossed on the C57BL/6J background for several generations. Mice were anesthetized with isoflurane and placed on a heating pad during surgery. A vascular clamp was applied only on the left renal pedicle to induce transient moderate ischemia for 30 min. Protocols were approved by the Animal Care Committee and the Canadian Council on Animal Care.
Histopathological and morphometric analysis. Mice were euthanized at different stages of reperfusion, and kidneys were fixed in formalin. Paraffin-embedded blocks were sectioned and stained with hematoxylin and eosin or sirius red. Morphometric (cyst) analysis was performed using hematoxylin and eosin sections of left IRI kidneys from non-Tg (n ϭ 38), transgenic Pkd1 extra2/39 (n ϭ 19), and Pkd1TAG6 (n ϭ 8) mice. Images from a Leica MZ12 microscope were processed by Northern Eclipse.
Cilia length was evaluated in formalin-fixed kidneys in cortical and medullary regions of IRI nontransgenic (n ϭ 6, n ϭ 3) and non-IRI non-Tg kidneys (n ϭ 10, n ϭ 5) as described in (23) . Images of cilia length (83-165 cilia/kidney) by DM5500B microscope were measured by Volocity.
Transcriptional analysis. RNA was extracted from left kidneys using TRIzol at 16 and 23 days and/or 3 mo postsurgery (Invitrogen). RNA integrity was confirmed on formaldehyde/agarose gels. Primers used for analysis are Pkd1 forward 5=-TCAATTGCTCCGGC-CGCTG, reverse 5=-CCAGCGTCTGAAGTAGGTTGTGGG; Pkd2 forward 5=-CGAGTCAGAAACGGATCCTGCTCCA, reverse 5=-CCAGTGACTGCTCCCATTCAGCTC; Hif1␣ forward 5=-TCAT-CAGTTGCCACTTCCCCAC, reverse 5=-CCGTCATCTGTTAGCA-CCATCAC; Ankrd37 forward 5=-ACAGGATGTCTTGGG-AGAAAC, reverse 5=-GGACATCACTGGCCACAA; Ctnnb1 forward 5=-TGAAGGCGTGGCAACATA, reverse 5=-CTGAAAGC-CGCTTCTTGTAATC; c-Myc forward 5=-CTGGAGATGATGAC-CGAGTTAC, reverse 5=-GAGAAACCGCTCCACATACA; and Gapdh forward 5=-AAGGTCATCCCAGAGCTGAA, reverse 5=-CTGCTTCACCACCTTCTTGA (served as a normalizer). Real-time PCR was performed using SYBR Select Master Mix (Applied Biosystems from Life Technologies) in ViiA 7 PCR System (Applied Biosystems) with the following conditions: 50°C 2 min, 95°C 2 min, and 40 cycles of 95°C 15 s and 60°C 1 min.
Protein expression analysis. For Western blotting, total protein kidney extracts for Pc1 were fractionated as described in (23) , and the glycosylation status (90 g) was assessed using EndoH (750 U, New England Biolabs). All other proteins were analyzed from total kidney extracts on 8% Tris-glycine gels. All proteins were transferred onto polyvinylidene difluoride membranes (VWR) and blocked with 5% PBST1X/milk or 5% TBST1X/BSA and incubated with an antibody, as described (23, 24) . Analysis of phospho-protein expression was carried out in the presence of a phosphatase inhibitor cocktail at different postreperfusion times (16 days, 23 days, and 3 mo). The following antibodies were used: Pc1 anti-LRR (7 e 12) antibody (Santa Cruz Biotechnology or Drs. Ward and Harris), c-Myc (Epitomics), tuberin (Santa Cruz Biotechnology), Pc2 YCC2 (Alabama P30 PKD Core), active, total ␤-catenin, total Erk (Millipore) and phospho-Erk, total Akt, phospho-S6K1T389, total S6K, P-AktT308, and P-AktS473 (Cell Signaling), collagen type IV (Abcam), and Gapdh (Abcam) as a loading control. Detection by ECL Prime and the Bio-Rad Chemi-Doc XRSϩ imaging system or by Kodak film was used for quantification of intensity of the bands (ImageQuant, ImageJ, Image Lab).
Immunohistochemistry. Formalin-fixed paraffin-embedded renal tissues (4 -5 m; n ϭ 4 mice) were processed as described (9) . Proliferation was assessed with the Ki67 marker as reported (9, 10) . A proliferative index was evaluated by quantification of positive signal over the total kidney surface (excluding cyst area) of the entire kidney section using Northern Eclipse software from ϫ100 images. Analysis of cellular c-Myc (rabbit polyclonal, Upstate), ␤-catenin (rabbit polyclonal, Millipore), and Hif1␣ (rabbit monoclonal, Abcam) expression was performed by incubation overnight at 4°C, then incubation for 1.5-2 h with secondary anti-rabbit biotin-conjugated antibody and signal detection using a Vectastain ABC kit and peroxidase substrate DAB kit (Vector Laboratories).
Statistical analysis. Correlation between cystic surface and cystic number was assessed by a Pearson r-test. Data are represented as means Ϯ SE, and the statistical significance of quantitative PCR and proliferation was analyzed using an unpaired two-tailed t-test. P Յ 0.05 was considered significant.
RESULTS

AKI causes renal cystogenesis.
Since IRI in Pkd1 dosagereduced mouse models was reported to promote cyst formation, we questioned whether cystogenesis could be accelerated in Pkd1 dosage-increased models and interrogated the molecular mechanism. Two sets of transgenic mouse lines were selected, one expressing Pkd1 full-length with mild dosageincreased Pkd1 TAG (line 6) at ϳ1.3-fold endogenous levels that develop cysts at 9 mo (23) , and the second a clinical-like mutant expressing Pkd1 extracellular domain, Pkd1 extra , at low (line 39) and high (line 2) levels that exhibits cysts at ϳ15-16 mo (24) . Unilateral left IRI was performed in 3-mo-old mice including control nontransgenic (non-Tg) littermates (Fig. 1A ). Mice were euthanized at three time points post-IRI, day 16, day 23, or 3-4 mo, before cyst detection in any of the three transgenic lines (Fig. 1B) .
Renal histological analysis was performed in transgenic and non-Tg mice. All IRI kidneys of Pkd1 extra (n ϭ 27) and Pkd1 TAG (n ϭ 9) mice displayed tubular dilatations and cysts (Fig. 1C) , consistent with IRI promoting cystogenesis in dosage-increased models as in dosage-reduced mouse models. Cysts were detected in the cortex, corticomedullary junction, and papilla of left transgenic kidneys. Noticeably, left kidneys of non-Tg mice (n ϭ 63) compared with sham-operated mice (n ϭ 20) also showed tubular and glomerular dilatations and cysts at days 16 and 23, and by 3 mo post-IRI some were overtly cystic whereas sham-operated kidneys were unaffected (Fig. 1, D and E) . Non-Tg and transgenic left kidneys displayed epithelial hyperplasia, infiltrates, tubular damage/atrophy, protein hyaline casts, and fibrosis. To determine whether transgenic clinical-like and/or dosage-increased Pkd1 lines are prone to more severe cystogenesis relative to non-Tg mice, the cystic surface (% of total area) was quantified in kidneys at 3 mo postreperfusion. Non-Tg and transgenic mouse lines had similar proportions of mice in each cystic severity subgroup (Fig.  1F, left) . Non-Tg and transgenic IRI kidneys were also monitored for the mean number of cysts per surface area and then subdivided into subgroups. The proportion of mice in each subgroup was relatively comparable for each genotype, suggesting no major difference in the initiation of cyst formation (Fig. 1F, right) . Notably, the cystic surface significantly correlated with the mean number of cysts for each subgroup (non-Tg r ϭ 0.90, P Ͻ 0.0001; Pkd1 extra r ϭ 0.72, P Ͻ 0.0005; Pkd1 TAG r ϭ 0.92, P Ͻ 0.001). These quantifications indicate that the transgenes had minimal effect on cystic phenotype initiation and/or progression. Based on our observation of renal epithelial hyperplasia and stimulated proliferation in ADPKD (26) and cystic mouse models (9, 23, 48) , we evaluated cell proliferation in IRI kidneys. Since the transgenic lines showed a similar range of cystic severity as non-Tg kidneys, we focused our analysis on non-Tg kidneys at 3 mo post-IRI (Fig. 1, G and H) . Proliferation was calculated as the number of Ki67-positive nuclei per surface area, corrected for the cystic surface. Non-IRI kidneys displayed few Ki67-positive cells sparsely within the parenchyma. In contrast, IRI kidneys displayed significantly increased Ki67-positive cells by three-to sixfold relative to non-IRI non-Tg (n ϭ 3; P Ͻ 0.05). Interestingly, a positive signal was detected in dilated and cystic tubules often in cell clusters but also in glomeruli and in the parenchyma, possibly resulting from a long-term repair program.
A
To assess renal repair processes, we monitored fibrosis and interstitial scarring in kidneys at 3 mo post-IRI. Both IRI non-Tg and transgenic Pkd1 extra left kidneys showed intense staining over the corticomedullary junction in the outer medulla, the most susceptible region to ischemia, as well as in the cortex and papilla (Fig. 1I ). Evidence of increased fibrosis was also evaluated for levels of collagen type IV by immunoblotting (Fig. 1J ). Fibrosis and collagen deposits provide evidence of maladaptive repair mechanism in both non-Tg and transgenic AKI kidneys.
Because cilia anomalies are associated with renal cysts and the stress response (5), we monitored cilia length in non-Tg kidneys at 3 mo post-IRI. The distribution of epithelial cilia length in the cortical and medullary regions was determined according to small intervals. The cilia length was similar in cells from the cortical region of IRI and non-IRI kidneys. In contrast, the medullary region of IRI kidneys showed a significantly higher proportion (10.9%) of cells with longer cilia (4 -5 m) than non-IRI left kidneys (6.2%) (Fig. 1K ), suggesting that ischemia also elicits mild stimulation of ciliogenesis.
Stimulation of Pc1/Pc2 signaling pathways. To investigate IRI molecular cystogenic mechanisms, Pkd1/Pc1 and Pkd2/ Pc2 expression was evaluated since their dysregulation can induce cystogenesis (23, 27, 36, 38, 46) . Analysis of IRI kidneys from non-Tg mice by real-time PCR showed a substantial increase in Pkd1 expression levels by about fourfold relative to the levels in sham non-Tg left kidneys (P Ͻ 0.005) ( Fig. 2A) . Consistently, IRI kidneys showed a major increase in Pc1 expression (ϳ3-4 fold) at 16 days post-IRI (Fig. 2B ) that was sustained at 23 days and 3 mo post-IRI. In contrast, contralateral right kidneys exhibited similar Pc1 expression levels to non-IRI mice at these time points. The Pkd extra 39 displayed as expected, from the transgene, elevated expression 1.3-to 2-fold Pc1 (Pc1 extra ) in the right kidneys (23, 24) . Pc1 expression was further increased (ϳ3-6 fold) in left IRI kidneys compared with contralateral kidneys at 23 days and 3 mo post-IRI. Similarly, the low Pkd1 dosage-increased Pkd1 TAG 6 line had clearly higher Pc1 levels in IRI left kidneys (ϳ3-5 fold) (Fig. 2B, right) . Of significance, both IRI non-Tg and Pkd1 TAG 6 kidneys display stimulated Pc1 expression in the same range but without reaching levels obtained in non-ischemic high dosage-increased Pkd1 TAG 26 kidneys (right) (23) .
To monitor whether the increased Pc1 protein by IRI was processed as the endogenous native Pc1, the most abundant GPS/GAIN-cleaved Pc1 form was analyzed for N-glycan modification with endoglycosidase H (endoH, E) treatment. Figure  2C shows a strong Pc1 endoH-resistant band (top, Pc1 NTF450 ), which is the mature GPS-cleaved form, and a weaker Pc1 endoH-sensitive (bottom, Pc1 NTF370 ) band, the immature form. A similar proportion of Pc1 endoH-resistant and -sensitive bands was detected in kidneys at day 16 and 3 mo post-IRI, suggesting that increased Pc1 in IRI kidneys is processed like the native endogenous Pc1.
We next assessed whether Pkd2/Pc2 expression was modulated in IRI renal cystogenesis in parallel with Pkd1/Pc1. IRI kidneys of non-Tg mice showed a mild but significant increase in Pkd2 expression level (P Յ 0.02) (Fig. 2D) . Notably, analysis of non-Tg mice showed increased Pc2 expression by 8-to 15-fold in IRI kidneys at all time points compared with non-IRI left kidneys (Fig. 2E) . Contralateral kidneys displayed similar Pc2 expression levels in non-Tg and transgenic mice. Similar to the IRI non-Tg kidneys, Pc2 expression levels in IRI Fig. 1 . Unilateral ischemia leads to cystic phenotype in nontransgenic (non-Tg) and transgenic mice. A: schematic illustration of the experiment time course. Ischemia was induced in the left kidney of male mice from Pkd1extra and Pkd1TAG transgenic lines and non-Tg controls. Mice were euthanized at 16 days (16d), 23 days (23d), and 3-4 mo (3m) post-IRI. B: representative kidney histology of non-ischemia-reperfusion injury (IRI) Pkd1 transgenic lines and non-Tg controls at 6 -8 mo of age (equivalent ϳ3 mo post-IRI) does not display a cystic phenotype. Tissues were stained with hematoxylin and eosin (H&E). Scale bars ϭ 500 m. C: left kidneys from transgenic Pkd1extra and Pkd1TAG mice with mild, intermediate, or severe cyst phenotype compared with contralateral right kidneys at 3m post-IRI. All left kidneys displayed infiltrates, hyperplasia, fibrosis, and cysts. Scale bars ϭ 500 m. D: IRI left kidneys from non-Tg mice showed at 16d evidence of tubular dilatations and at 23d and 3m presence of protein deposits (open arrowhead), tubular cysts (one star), glomerular (2 stars), hyperplasia (black arrowhead), and infiltrates (arrow), but not in contralateral kidneys. Stain used was H&E. Magnification ϫ10 except 23d left kidneys at ϫ32. E: representative left and right kidney sections of non-Tg sham-operated mice at 16d, 23d, and 3m do not exhibit any obvious anomalies. Stain used was H&E. Scale bars ϭ 500 m. F: semiquantification of cystic phenotype variability in IRI kidneys (ϩ) of non-Tg (Ϫ; n ϭ 38) and transgenic mice (Pkd1extra2/39, n ϭ 19; Pkd1TAG6, n ϭ 8). Percentage of mice with "small" Ͻ5%, "intermediate" 5-15%, or "extensive" Ն15% renal cystic surface (% total area) in transgenic and non-Tg mice (left) displayed analogous profiles. Percentages of transgenic and non-Tg mice were classified in groups as "low" (Ͻ2), "moderate" (2-5), or "high" (Ն5) number of cysts/mm 2 (right). The percentage of mice in the extensive/high cystic group of transgenic lines was not significantly increased relative to non-Tg mice. G: evaluation of epithelial proliferation in IRI (ϩ) and non-IRI (Ϫ) left kidneys of non-Tg (Ϫ) mice by Ki67 immunostaining. IRI kidneys showed higher numbers of proliferative nuclei per surface compared with non-IRI kidneys. *P Ͻ 0.05. H: representative renal histological sections of IRI and non-IRI left kidneys from non-Tg mice immunostained with Ki67 for proliferation analysis. I: assessment of fibrosis by Sirius red staining of left renal sections from non-Tg and Pkd1TAG6 line at 3m post-IRI relative to non-Tg non-IRI controls. IRI kidneys showed the presence of collagen with a particularly intense signal at the corticomedullary border but also in the cortex and papilla. Scale bars ϭ 100 m. J: evaluation of collagen deposits by immunoblotting of total extracts from left IRI and contralateral kidneys 3m post-IRI. Non-Tg and Pkd1extra transgenic mice exhibit major increased collagen IV expression levels in left IRI compared with right kidneys. K: cilia length distribution from renal epithelium at 3m post-IRI showed that the percentage of cells with cilia Ն4 m to 5 m in IRI (ϩ) non-Tg (Ϫ) kidneys (black hatched bars; n ϭ 6) was comparable to the non-IRI (Ϫ) non-Tg (Ϫ) kidneys (grey hatched bars; n ϭ 10) in the outer (o) cortical regions whereas the percentage of cells with cilia Ն4 to 5 m in IRI (ϩ) non-Tg (Ϫ) kidneys (black bars, n ϭ 3) was significantly increased compared with non-IRI (Ϫ) non-Tg (Ϫ) kidneys (grey bars; n ϭ 5) in the inner (i) medullary regions. *P Ͻ 0.05, **P Ͻ 0.005. kidneys of Pkd extra transgenic lines were markedly increased. These data on IRI kidneys revealed long-term and strong dosage-increase levels of both Pc1 and Pc2 following stress conditions.
A D C E -E -E -E -E
Persistent ischemic response following postreperfusion. Based on similar responses of IRI non-Tg and transgenic kidneys stimulating Pc1 as well as Pc2 expression, we focused our studies on non-Tg kidneys. To determine whether AKI induced a persistent hypoxic and/or repair response, we assessed Hif1␣ transcript levels from 16 days post-IRI (Fig. 3A) . Transcriptional expression analysis of Hif1␣ showed a significant approximately threefold increase in IRI non-Tg kidneys (P Ͻ 0.0001) relative to sham left kidneys (Fig. 3A) , confirming that a Hif1␣ signal is triggered by IRI. Noticeably, Hif1␣ levels remained elevated at 23 days and ϳ3 mo by more than twofold (Fig. 3A) . Consistently, Ankrd 37, a Hif1␣ transcriptional target, was also significantly stimulated (Fig. 3B) . Since Hif1␣ protein is reported short lived (49), we monitored cellular localization of Hif1␣ in IRI kidneys by immunostaining. Figure 3C shows a strong Hif1␣ signal on the entire IRI non-Tg renal sections. In particular, a markedly intense nuclear signal was detected in cystic and in dilated tubules compared with a very weak and cytoplasmic signal observed in non-IRI kidneys. This persistent ischemic response points to activation of several regulatory pathways.
AKI as a modulator of the mTOR cascade. Since cystogenesis by deregulation of Pc1 and Pc2 respond to mTOR inhibitors (43), we interrogated regulators of the mTOR pathway in AKI-induced cystogenesis. We first investigated the activation status of Erk. Both P-Erk (T202/Y204) and total Erk expression was substantially elevated in IRI kidneys of non-Tg and transgenic mice at all ages post-IRI (Fig. 4, A and B) , suggesting that IRI modulates their transcriptional regulation. The ratio of P-Erk to total Erk of non-Tg left IRI kidneys was not significantly increased relative to non-IRI kidneys, suggesting that Erk negative control on mTOR is not a major regulator of IRI cystogenesis. We then monitored whether Akt activation could regulate mTOR through negative regulation. Total Akt levels were consistently increased (ϳ10-fold) in left IRI compared with non-IRI kidneys. Interestingly, P-AktT308 and P-AktS473 levels were at 16 and 23 days post-IRI equivalent or slightly increased in IRI non-Tg left kidneys relative to non-IRI kidneys (Fig. 4, C and D) . At 3 mo post-IRI, both P-AktT308 and P-AktS473 displayed higher levels. While absolute P-Akt levels may play a role in the late post-IRI stage, the lack of increase in P-Akt to total Akt ratio would suggest otherwise.
We then determined whether the mTOR effector tuberin, a known key cystogenic factor and interacting partner of Pc1, is dysregulated. In fact, tuberin expression was not decreased as expected for a role in cystogenesis but strongly stimulated (7-to Ͼ20-fold) from early tubular dilatation stages onward in left IRI kidneys relative to contralateral non-IRI kidneys (Fig. 4E) . Similarly, Pkd1 extra IRI kidneys exhibited increased tuberin expression (ϳ8-to 11-fold) at 3 mo post-IRI ( Fig. 4F ; reprobed from Fig. 4B ).
To determine whether mTOR is activated, we analyzed the phosphorylation status of the downstream effector ribosomal subunit protein S6K (P-S6K1, Thr389) and total S6K. Levels of total S6K were similar in both IRI and non-IRI kidneys (Fig.  4G) . By contrast, P-S6K1T389 levels were strongly induced (6-to 11-fold) in left IRI kidneys relative to contralateral and non-IRI kidneys. These data indicated substantial activation of the mTOR complex 1 (mTORC1) pathway in response to AKI.
AKI stimulates the Wnt canonical signaling pathway. Since tuberin and Pc1 can cross talk with GSK3 of the Wnt canonical pathway (21, 22), we evaluated ␤-catenin regulation. As shown in Fig. 5A , transcription of the Ctnnb1 gene encoding ␤-catenin was stimulated by 1.5-to 2-fold in 3 mo post-IRI relative to sham-operated left kidneys (P Յ 0.02). Analysis of IRI non-Tg kidneys showed a striking increase in total ␤-catenin expression of Ͼ10-fold compared with the almost undetectable levels in contralateral kidneys from early stages of tubular dilatations to 3 mo post-IRI ( Fig. 5B; reprobed from Fig. 4B ). Most interestingly, levels of active ␤-catenin were even more enhanced than total ␤-catenin in IRI kidneys with a ratio of active to total ␤-catenin of 2-8-fold (Fig. 5B, top) . Similarly, IRI Tg kidneys showed stimulation of active and total ␤-catenin expression (Fig. 5B, bottom) . To determine the cellular localization of ␤-catenin expression, IRI kidneys at 3 mo postreperfusion were analyzed by immunostaining (Fig. 5C) . Compared with the weak signal detected in non-IRI kidneys, a strong ␤-catenin signal was detected over the epithelium of cystic and showed a 5-to 10-fold stimulation compared with shamoperated kidneys (P Յ 0.0002) (Fig. 5D) . Consistently, c-Myc protein expression was markedly upregulated (3-to 5-fold) in IRI non-Tg and transgenic kidneys while barely detectable in control kidneys ( Fig. 5E ; reprobed from Fig. 4B ). Noticeably, the additional ϳ42-kDa band likely corresponding to c-Myc cytoplasmic cleaved-form, Myc-nick (7), was also elevated by 2-to 5-fold. We then monitored c-Myc cellular localization in the left kidneys post-IRI. A more pronounced and generalized c-Myc signal was detected on the entire IRI non-Tg compared with non-IRI kidneys (Fig. 5F ). Interestingly, a c-Myc signal was observed in both cytoplasmic and nuclei, consistent with expression of both the cleaved and full-length forms. As determined for ␤-catenin cellular localization, the most intense c-Myc expression was detected in dilated to cystic tubules and in parietal cells of glomeruli. These results suggest that ␤-catenin and/or c-Myc levels and localization could be cystogenic in AKI.
DISCUSSION
The original intent of these studies was to determine whether AKI is a modifier of cystogenesis in late-onset clinical and mild dosage-increased Pkd1 alleles with a focus on progressive and long-term outcomes. Our study shows that ischemia can be an inducer and not only a modifier of cystogenesis in non-Tg and in two late-onset Pkd1 mouse models. This AKI-induced cystogenic mechanism cross talks with Pc1 and Pc2 and targets activation of the mTOR and Wnt pathways. We uncovered that AKI shares similar cellular responses and a global molecular regulatory network with PKD.
Particularly striking is the 100% penetrance of renal tubular and glomerular cystogenesis in the transgenic and non-Tg IRI kidneys along with tubular atrophy, inflammation, fibrosis, and longer cilia. The comparable range of cystic severity from the transgenic as well as non-Tg mice indicates that the transgene does not significantly potentiate the phenotype. This finding may appear inconsistent with the reported accelerated cysts in the Pkd1 dosage-reduced mouse models at 2 or 10/14 wk following bilateral ischemic or toxic injury, respectively, and not in controls. While the difference in earlier timing of cyst appearance between the dosage-reduced mouse models may be attributed to the type of renal injury, the absence of cysts in controls points to another mechanism. Indeed, the use of a mixed genetic background in the dosage-reduced mouse studies could have played a crucial role as the 129SV mouse strain was shown to be more resistant to IRI damage than the C57BL/6 mice (29). The unilateral moderate ischemic conditions in our control and transgenic mice on the C57BL/6 genetic background led to systematic renal abnormalities, consistent with a previous report (4) . IRI in the Pkd1 dosagereduced kidneys appears as an additional procystogenic contributor whereas in C57BL/6 kidneys, it is sufficient to trigger a cystogenic mechanism. Independently of the genotype, post-IRI kidneys were incapable of complete recovery from injury despite presumably active renal repair programs and progressed to cystic disease within a few weeks of reperfusion (51). Our data not only support previous observations in mice and rats (4, 13, 34) but also highlight the contribution of genetic factors in the increase susceptibility of AKI patients to CKD.
While stimulation of Hif1␣, a sensor for oxygen-deprived levels, was anticipated subsequent to ischemia or cellular hypoxia, the elevated transcript levels for several weeks revealed a transition from acute renal injury to chronic renal injury. Previous studies showed that Hif1␣ is not only increase transcriptionally following cellular hypoxia but also transiently stabilized in the early phase of postreperfusion following injury during the kidney repair process (8, 49) . However, persistence of Hif1␣ transcriptional expression detected herein from the early tubular dilatation stage onward and increased Hif1␣ downstream target expression suggest an absence of switching off the repair process, maladaptive repair, or activation of injury-associated secondary cascades (54) . Hif1␣ strong nuclear sublocalization supports a regulatory role in the cystogenic process. Interestingly, increased expression of Hif1␣ was detected in late stages of human ADPKD and also in PKD animal models (2, 3). The sustained increase in Hif1␣ expression alone is unlikely responsible for injury-induced cystogenesis in our IRI control and transgenic mice, since overexpression of Hif1␣ causes renal cysts in older animals at or beyond 1 yr of age (14) . Nonetheless, Hif1␣-stimulated expression could be a significant modifier of or contributor to the IRI cystogenic pathway.
Of importance, the persistent and substantial renal transcriptional and translational upregulation of Pkd1/Pc1 in control and transgenic mice as well as major stimulation of Pc2 indicate that AKI controls Pc1 and Pc2 levels via two mechanisms, transcriptional activation and protein stability, respectively. Previous reports observed stimulation of Pc2 and/or Pc1 in the very early post-IRI phase that may participate in the repair process (33, 39) . However, the sustained and high levels of Pc2 detected for several weeks are likely to have cystogenic potential since mild Pkd2/Pc2 upregulation in transgenic mice can cause cysts by 6 -18 mo of age (36) . Concurrently, in- Fig. 4 . Activation of the mammalian target of rapamycin (mTOR) signaling in IRI kidneys. A: immunoblot shows increase in both P-Erk and total Erk1/2 (42/44 kDa) levels in IRI left kidneys of non-Tg mice relative to right and non-IRI non-Tg kidneys. Histograms show P-Erk/Gapdh, Erk/Gapdh, and P-Erk/Erk fold-induction of left kidneys at various time points. B: IRI left kidneys of non-Tg and Pkd1extra39 mice show increase in both P-Erk and total Erk1/2 levels relative to non-IRI right kidneys (immunoblot reprobed from Fig. 2E ). Histograms show P-Erk/Gapdh, Erk/Gapdh, and P-Erk/Erk relative ratios for right and left kidneys 3m post-IRI. C: IRI left non-Tg kidneys exhibit from 16d onward increased total Akt levels and a considerable stimulation of P-Akt 308 and P-Akt creased levels of Pkd1 and the Pc1 mature form as detected in IRI kidneys can also trigger cystogenesis as shown in Pkd1 transgenic mice targeted systemically or specifically to the kidney (23, 46) . The same range of Pc1 increased expression in non-Tg and transgenic could explain the similar phenotypic progression. Our data show that acute ischemic injury upregulates both polycystin responsible for ADPKD after reperfusion which could individually or together act as important modifiers or account for the cystogenic phenotype.
Our studies show dysregulation of the mTOR signaling cascade in ischemic kidneys as observed in cystic mouse models and human ADPKD tissues (15, 40, 42, 45) --increased levels of phospho and total Erk in all and Akt in late-stage postreperfusion provide a potential regulatory connection to the mTORC1 pathway. This pattern of P-Erk and P-Akt patterns in IRI kidneys mimic that reported in a renal cystic mouse model (15) . Of interest, such AKI mice with physiological overexpression of Pc1 and Erk also indicate that Pc1 does not or is not sufficient to inhibit Erk expression or signaling, as suggested from in vitro data (12) . Tuberin activity may also be modulated by alternative factors of this cascade since it was reported that exogenous Pc1 can interact with tuberin and the mTOR pathway become activated (42) . Accordingly, activation of S6K, the mTORC1 downstream target, by ischemic stress is possibly a repair response as more pronounced tubular damage is triggered by IRI in mTORC1-deficient kidneys and in rapamycin-treated animals (17, 28) . Our findings in renal ischemic stress are also consistent with mTOR cascade activation and delayed cystogenesis by mTOR inhibitors in several cystic non-and orthologous Pkd1 mouse models (15, 42, 43 ). An important insight into our analysis is that in the face of markedly elevated Pc1, mTORC1 pathway is not downregulated but in fact is upregulated in vivo. Coactivation of mTOR and Hif1␣ in response to renal IRI and downregulation of Hif1␣ with inhibitors of mTOR (20, 31) indicate that Hif1␣ signals into the mTOR pathway to adapt cell metabolism and protein synthesis responses, as shown in the proposed model (Fig. 6) . Collectively, our data clearly suggest that the mTOR pathway is implicated in repair and/or progression of ischemic renal cystic pathology. Our studies determine that the Wnt canonical pathway in AKI is likely a key and critical mechanism and possibly a modulator of the mTORC1 cascade in the ischemic-induced phenotype. In IRI kidneys, Wnt signaling in adulthood becomes activated possibly through Pc1 stimulation that can inhibit GSK3 activity (22) . Consistently, the strong and sustained activation of ␤-catenin from early to late postreperfusion shows that the Wnt canonical pathway is stimulated during renal injury and/or repair. This finding correlates with a more severe AKI response in ␤-catenin-deficient animals (53). However, persistent upregulation of ␤-catenin can be responsible for development of the cystogenic phenotype, as previously observed (41) . Conversely, cystic mouse models and human ADPKD tissues upon Pc1 dysregulation induce activation of the Wnt/␤-catenin pathway (25, 30, 35 ) (Trudel M and Kurbegovic A, unpublished observations). Significantly, the strong induction of c-Myc, a downstream effector of ␤-catenin (19), supports implication of the Wnt canonical pathway. Upregulation of both full-length c-Myc and Myc-nick could play a role following ischemic stress in transcriptional regulation and in cell survival/metabolism, respectively (7, 16) . Moreover, elevated c-Myc levels were shown in several cystic mouse models (11, 52) , including renal or systemic dosage-increase Pkd1 mouse models (23, 46) and in human ADPKD tissues (26) . Most importantly, renal c-Myc overexpression in transgenic mice was shown to induce PKD (47), pointing to c-Myc as a potential causative IRI cystogenic factor. Together, these results suggest that the Wnt canonical pathway implicated in ADPKD is also determinant in the AKI-induced signaling network.
Particularly remarkable is the parallel response and longterm signaling of AKI and ADPKD. These similarities suggest that ischemic stress plays an important role in ADPKD. Re- Fig. 5 . IRI induces Wnt signaling pathway activation in kidneys. A: expression of Ctnnb1 transcript normalized to Gapdh in IRI and non-IRI sham-operated non-Tg left kidneys was performed at 3m postsurgery using quantitative PCR. Ctnnb1 expression in IRI kidneys (n ϭ 7) was increased Ϸ2-fold relative to sham kidneys (n ϭ 6) set at 1. *P Ͻ 0.05. B: unphosphorylated active and total ␤-catenin in IRI non-Tg left kidneys were markedly enhanced from 16d onward (top) whereas the contralateral and non-IRI kidneys were barely detectable. Similarly, active and total ␤-catenin in IRI left kidneys of non-Tg and Pkd1extra (line 39; bottom/reprobed from cently, AKI and chronic kidney disease were proposed to be interconnected human syndromes (6) . Our findings suggest that recurrent injury in ADPKD and Pkd1 dosage-dependent mouse models trigger cystogenesis at least in part via chronic kidney ischemia. Molecularly, the convergence of several causative cystogenic/PKD factors like Pc1, Pc2, Hif1␣, ␤-catenin, and c-Myc induced a few weeks after reperfusion supports cross talk between AKI and ADPKD signaling pathways.
In conclusion, we demonstrated that AKI in mice remarkably reproduces several of the typical ADPKD phenotypic features and signaling pathways. Most importantly, our study warrants future prospective cohort studies on the AKI prognostic outcome with ADPKD effectors.
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